Alterity Therapeutics Limited
PRNAF
$0.0101
$0.0065180.56%
| Weiss Ratings | PRNAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | PRNAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | PRNAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -2.40 | |||
| Price History | PRNAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | 0.00% | |||
| 60-Day Total Return | 180.56% | |||
| 90-Day Total Return | 180.56% | |||
| Year to Date Total Return | 180.56% | |||
| 1-Year Total Return | 4,950.00% | |||
| 2-Year Total Return | 87.04% | |||
| 3-Year Total Return | -30.82% | |||
| 5-Year Total Return | 10,000.00% | |||
| 52-Week High % Change | 0.00% | |||
| 52-Week Low % Change | 245.89% | |||
| Price | PRNAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.01 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Jun 12, 2024 | |||
| 52-Week High Price (Date) | Jan 21, 2025 | |||
| Valuation | PRNAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 33.21M | |||
| Enterprise Value | 30.45M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | 0.00 | |||
| Earnings Per Share Growth | -15.15% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 25.25 | |||
| Price/Book (Q) | 11.22 | |||
| Enterprise Value/Revenue (TTM) | 9.03 | |||
| Price | $0.01 | |||
| Enterprise Value/EBITDA (TTM) | -1.64 | |||
| Enterprise Value/EBIT | -1.64 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | PRNAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 5.31B | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | PRNAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 61 3 9349 4906 | |||
| Address | 350 Collins Street Melbourne, VIC 3000 | |||
| Website | alteritytherapeutics.com | |||
| Country | Australia | |||
| Year Founded | 1997 | |||
| Profitability | PRNAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -551.04% | |||
| Profit Margin | -531.22% | |||
| Management Effectiveness | PRNAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -78.11% | |||
| Return on Equity | -- | |||
| Income Statement | PRNAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | 2.46M | |||
| Revenue Per Share | $0.00 | |||
| Gross Profit (TTM) | 2.34M | |||
| EBITDA (TTM) | -13.51M | |||
| EBIT (TTM) | -13.53M | |||
| Net Income (TTM) | -13.05M | |||
| Net Income Avl. to Common (TTM) | -13.05M | |||
| Total Revenue Growth (Q YOY) | -15.53% | |||
| Earnings Growth (Q YOY) | -10.22% | |||
| EPS Diluted (TTM) | 0.00 | |||
| EPS Diluted Growth (Q YOY) | 37.50% | |||
| Balance Sheet | PRNAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 2.81M | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 6.46M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 4.82M | |||
| Current Ratio (Q) | 3.838 | |||
| Book Value Per Share (Q) | $0.00 | |||
| Total Assets (Q) | 6.53M | |||
| Total Current Liabilities (Q) | 1.68M | |||
| Total Debt (Q) | 65.50K | |||
| Total Liabilities (Q) | 1.71M | |||
| Total Common Equity (Q) | 4.82M | |||
| Cash Flow | PRNAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 0.00 | |||
| Cash from Financing (TTM) | 5.57M | |||
| Net Change in Cash (TTM) | -5.14M | |||
| Levered Free Cash Flow (TTM) | -5.88M | |||
| Cash from Operations (TTM) | -10.86M | |||
